BIOLIFE SOLUTIONS INC

Listed Company
BLFSCIK 0000834365NasdaqLarge AcceleratedElectromedical & Electrotherapeutic ApparatusDelawareFY ends Dec 31
Period
FY 2025
Revenue
Net Income
$-4.59M
Total Assets
Equity
Shares Out
48.86M
Op. Cash Flow
$20.11M

Business

BioLife Solutions Inc develops, manufactures, and markets bioproduction products and services that improve and de‑risk biologic manufacturing, distribution, and transportation for the cell and gene therapy industry. Its products include biopreservation media (HypoThermosol FRS, CryoStor), human platelet lysate, cryogenic vials and fill machines, cloud‑connected evo shippers, and ThawSTAR automated thawing devices. It operates a single bioproduction business focused on cell processing and evo/thaw devices, supported by R&D, manufacturing, and quality systems. It sells globally—primarily in the United States and EMEA—via direct sales, regional distributors, and courier logistics partnerships.

Summary from filing dated 2025-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts
ConceptTrend
FY 2025
2025-12-31
FY 2024
2024-12-31
FY 2023
2023-12-31
FY 2022
2022-12-31
FY 2021
2021-12-31
Revenue96756876119
Cost of revenue342527
Gross profit625041
General and administrative4641433334
Sales and marketing109111214
Research and development856912
IPR&D expense1600
Intangible asset amortization263,000263,000148
Change in fair value of contingent consideration00−2−53
Total operating expenses79555982154
Operating loss−17−4−17−6−35
Interest income (expense), net3−766,000−1−284,000−485,000
Other income2494,0001662,000289,000
Change in fair value of investments0−40697,0000
Gain on settlement of Global Cooling escrow00500
Total other income (expense), net5−4516
Loss from continuing operations before income tax expense (benefit)−12−9−12−5−29
Income tax expense (benefit)49,000−38,000−64,000520
Loss from continuing operations−12−9−12388,000
Income (loss) from discontinued operations before income tax expense8−11−56−140
Income tax expense0132,000233,000−214,000
Income (loss) from discontinued operations8−11−56−140
Net loss−5−20−68−140−9
Continuing operations (in dollars per share)−0.25−0.19−0.280.01
Discontinuing operations (in dollars per share)0.16−0.25−1.27−3.3
Net loss (in dollars per share)−0.09−0.44−1.55−3.29−0.23
Continuing operations (in dollars per share)−0.25−0.19−0.280.01
Discontinuing operations (in dollars per share)0.15−0.25−1.27−3.26
Net loss (in dollars per share)−0.1−0.44−1.55−3.25−0.23
Basic (in shares)4846444239
Diluted (in shares)4946444339

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro